Clinical Trial Update: A Global Phase 3 Study of Orelabrutinib+BR Vs.BR in Pts with TN MCL [Phase 3]

View source ↗

Summary

This ClinicalTrials.gov listing describes a global Phase 3 study evaluating orelabrutinib plus bendamustine-rituximab (BR) versus BR alone in patients with mant…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Orelabrutinib (orelabrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: InnoCare Pharma Inc. | Conditions: Mantle Cell Lymphoma | Phase 3 | Status: RECRUITING